Loading…
Current state of treatment for primary cutaneous melanoma
The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many pati...
Saved in:
Published in: | Clinical and experimental medicine 2004-10, Vol.4 (2), p.65-77 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3 |
---|---|
cites | |
container_end_page | 77 |
container_issue | 2 |
container_start_page | 65 |
container_title | Clinical and experimental medicine |
container_volume | 4 |
creator | Chung, E S Sabel, M S Sondak, V K |
description | The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment. |
doi_str_mv | 10.1007/s10238-004-0040-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67237053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67237053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</originalsourceid><addsrcrecordid>eNpdUE1LxDAUDKK46-oP8CLFg7fqS9I0yVGW9QMWvOg5pMkr7NKPNUkP_ntbWhA8PN7jMTPMDCG3FB4pgHyKFBhXOUAxDeTijKyp0DTXgqnz5VZKw4pcxXgEoEJxuCQrKkrJdMHXRG-HELBLWUw2YdbXWQpoUzu96j5kp3BobfjJ3JBsh_0QsxYb2_WtvSYXtW0i3ix7Q75edp_bt3z_8fq-fd7njpcy5ayEikqmJCt8wZnXyLQQgA49esvLWrm68lVNsShd5S0wadEJz6ymRQGeb8jDrHsK_feAMZn2EB02zezHjEm4BMFH4P0_4LEfQjd6M4xDqZjS5QiiM8iFPsaAtVkSGgpmKtXMpZqx0GnAiJFztwgPVYv-j7G0yH8B8CFyCA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230682896</pqid></control><display><type>article</type><title>Current state of treatment for primary cutaneous melanoma</title><source>Springer Link</source><creator>Chung, E S ; Sabel, M S ; Sondak, V K</creator><creatorcontrib>Chung, E S ; Sabel, M S ; Sondak, V K</creatorcontrib><description>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-004-0040-5</identifier><identifier>PMID: 15672943</identifier><identifier>CODEN: CEMLBA</identifier><language>eng</language><publisher>Italy: Springer Nature B.V</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Cancer Vaccines - therapeutic use ; Clinical trials ; Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use ; Humans ; Immunology ; Interferon-alpha - therapeutic use ; Lymphatic Metastasis ; Melanoma - secondary ; Melanoma - therapy ; Recombinant Proteins ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Tumors</subject><ispartof>Clinical and experimental medicine, 2004-10, Vol.4 (2), p.65-77</ispartof><rights>Copyright Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15672943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, E S</creatorcontrib><creatorcontrib>Sabel, M S</creatorcontrib><creatorcontrib>Sondak, V K</creatorcontrib><title>Current state of treatment for primary cutaneous melanoma</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Clinical trials</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Immunology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lymphatic Metastasis</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Recombinant Proteins</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Tumors</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdUE1LxDAUDKK46-oP8CLFg7fqS9I0yVGW9QMWvOg5pMkr7NKPNUkP_ntbWhA8PN7jMTPMDCG3FB4pgHyKFBhXOUAxDeTijKyp0DTXgqnz5VZKw4pcxXgEoEJxuCQrKkrJdMHXRG-HELBLWUw2YdbXWQpoUzu96j5kp3BobfjJ3JBsh_0QsxYb2_WtvSYXtW0i3ix7Q75edp_bt3z_8fq-fd7njpcy5ayEikqmJCt8wZnXyLQQgA49esvLWrm68lVNsShd5S0wadEJz6ymRQGeb8jDrHsK_feAMZn2EB02zezHjEm4BMFH4P0_4LEfQjd6M4xDqZjS5QiiM8iFPsaAtVkSGgpmKtXMpZqx0GnAiJFztwgPVYv-j7G0yH8B8CFyCA</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Chung, E S</creator><creator>Sabel, M S</creator><creator>Sondak, V K</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Current state of treatment for primary cutaneous melanoma</title><author>Chung, E S ; Sabel, M S ; Sondak, V K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Clinical trials</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Immunology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lymphatic Metastasis</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Recombinant Proteins</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, E S</creatorcontrib><creatorcontrib>Sabel, M S</creatorcontrib><creatorcontrib>Sondak, V K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>PHMC-Proquest健康医学期刊库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Proquest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, E S</au><au>Sabel, M S</au><au>Sondak, V K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current state of treatment for primary cutaneous melanoma</atitle><jtitle>Clinical and experimental medicine</jtitle><addtitle>Clin Exp Med</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>4</volume><issue>2</issue><spage>65</spage><epage>77</epage><pages>65-77</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><coden>CEMLBA</coden><abstract>The incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.</abstract><cop>Italy</cop><pub>Springer Nature B.V</pub><pmid>15672943</pmid><doi>10.1007/s10238-004-0040-5</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1591-8890 |
ispartof | Clinical and experimental medicine, 2004-10, Vol.4 (2), p.65-77 |
issn | 1591-8890 1591-9528 |
language | eng |
recordid | cdi_proquest_miscellaneous_67237053 |
source | Springer Link |
subjects | Adjuvants, Immunologic - therapeutic use Cancer Vaccines - therapeutic use Clinical trials Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Humans Immunology Interferon-alpha - therapeutic use Lymphatic Metastasis Melanoma - secondary Melanoma - therapy Recombinant Proteins Skin Neoplasms - pathology Skin Neoplasms - therapy Tumors |
title | Current state of treatment for primary cutaneous melanoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A08%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20state%20of%20treatment%20for%20primary%20cutaneous%20melanoma&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Chung,%20E%20S&rft.date=2004-10-01&rft.volume=4&rft.issue=2&rft.spage=65&rft.epage=77&rft.pages=65-77&rft.issn=1591-8890&rft.eissn=1591-9528&rft.coden=CEMLBA&rft_id=info:doi/10.1007/s10238-004-0040-5&rft_dat=%3Cproquest_cross%3E67237053%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c367t-260b1728724d432d9e29550ecededa36f8cfbdbf1e46cbda027aec5d2a91440d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230682896&rft_id=info:pmid/15672943&rfr_iscdi=true |